Abstract
In vitro 5-hydroxytryptamine (5-HT) cause both a shape and aggregation of human platelets. Few studies have been reported on 5-HT-induced platelet aggregation in patients with peripheral or cerebrovascular disease, although these patients have been reported to have enhanced platelet activity [1–6] and show hyperaggregability in response to known aggregating agents [7–9].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Handin RI, McDough M, Lesch M. (1978): Elevation of platelet factor four in acute myocardial infarction: measurements by radioimmunoassay. J. Lab clin Med 91: 340–349.
Green LH, Scroppian E, Handin RI (1980): Platelet activation during exercise-induced myocardial ischaemia. New Engl J. Med 302: 193–197.
Schwartz MB, Hangier J, Timmons S, Freisinger GC (1980): Platelet aggregates in ischaemic heart disease. Thromb Haemostasis 434: 185–188.
Baele G, Bogaerts H, Clements DL, Pannier peripheral arterial disease. Thromb Res 23: 215–223.
Rotmensch HH, Vlasses PH, Carpentier KL, D’Amelia LF, Swanson BN, Ferguson RK (1983): Plasma Platelet products and exercise-induced myocardial ischaema. J Lab clin Med 102: 63–69.
De Cree J, Leempoels J, Demoen B, Roels V, Verhaegen H (1985): The effects of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular disease. Agents and Actions 16: 5, 313–317.
Steele PP, Welly HS, Davies H, Genton E (1973): Platelet function studies in coronary artery disease. Circulation 48: 1194–1200.
Dreyfuss F. Zahavi J (1973): adenosine diphospate-induced platelet aggregation in myocardial infarction and ischaemic heart disease. Atherosclerosis 17: 107–120.
Salky M, Dugdale M (1973): Platelet abnormalities in ischaemic heart disease. Am J Cardiol 32: 612–617.
Blackburn TP, Thornber CW, Pearce RJ, Cox B, (1988): In vitro pharmacology of ICI 170,809 — A new 5-HT2antagonist. FASEB journal 2 (5):A1404,6441.
De Clerk F, van Neuten JM (1982): Platelet-mediated vascular contractions: Inhibition of the serotonergic component by ketanserin. Thrombs Res 27: 713–723.
Nevelsteen A, Loots W, De Clerk F, De Gryse A (1984): Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2receptor antagonist. Archs int Pharmacodyn Ther 270: 260–279.
Blackshear JL, Orlandi S, Garnic JD, Hollenberg NK (1983): Serotonin induces large artery spasm in vivo via 5-HT2 receptors. Circulation 68:III-197, Abs. 798.
Verheyen V, Vlaminckx E, Lauwers F, Van Den Broeck C, Wouters L (1984): Serotonin-induced blood flw changes in the rat hind legs after unilateral ligation of the femoral artery. Inhibition by the S2-receptor antagonist ketanserin. Pharmacodyn Ther 270: 280–294.
Hollenberg NK (1988): Serotonin and vascular responses. Ann rev Pharmacol Toxicol 28: 41–59.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Blackburn, T.P., Haworth, S.J., Jessup, C.L., Morton, P.B., Williams, C. (1990). ICI 170809, A selective 5-hydroxytryptamine antagonist, inhibits human platelet aggregation in vitro and ex vivo . In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (eds) Cardiovascular Pharmacology of 5-Hydroxytryptamine. Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine, vol 106. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0479-8_40
Download citation
DOI: https://doi.org/10.1007/978-94-009-0479-8_40
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6701-0
Online ISBN: 978-94-009-0479-8
eBook Packages: Springer Book Archive